2025
Understanding eyebrow and eyelash involvement in patients with alopecia areata and responsiveness to treatment with baricitinib
Mostaghimi A, Craiglow B, King B, Shapiro J, Ko J, Tosti A, Ohyama M, Brogan Y, Yu G, Sontag A, Somani N. Understanding eyebrow and eyelash involvement in patients with alopecia areata and responsiveness to treatment with baricitinib. British Journal Of Dermatology 2025, ljaf088. PMID: 40179237, DOI: 10.1093/bjd/ljaf088.Peer-Reviewed Original ResearchBaricitinib 4 mgBaricitinib 2 mgHair-bearing sitesAlopecia areataResponse rateBenefit of baricitinibTreated with baricitinibRandomised to placeboPlacebo-controlled trialResponse to treatmentScalp hair lossSALT scoreDouble-blindClinical presentationBaricitinib treatmentTreatment successHair regrowthBaricitinibBaseline severityPatientsClinician reportsHair lossPlaceboPooled dataScalpLow-Dose Oral Minoxidil Initiation for Patients With Hair Loss
Akiska Y, Mirmirani P, Roseborough I, Mathes E, Bhutani T, Ambrosy A, Aguh C, Bergfeld W, Callender V, Castelo-Soccio L, Cotsarelis G, Craiglow B, Desai N, Doche I, Duque-Estrada B, Elston D, Goh C, Goldberg L, Grimalt R, Jabbari A, Jolliffe V, King B, LaSenna C, Lenzy Y, Lester J, Lortkipanidze N, Sicco K, McMichael A, Meah N, Mesinkovska N, Miteva M, Mostaghimi A, Ovcharenko Y, Piliang M, Piraccini B, Rakowska A, Salkey K, Schmidt A, Shapiro J, Sibbald C, Sinclair R, Suchonwanit P, Taylor S, Tosti A, Vañó-Galván S, Wall D, Fu J. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss. JAMA Dermatology 2025, 161: 87-95. PMID: 39565602, DOI: 10.1001/jamadermatol.2024.4593.Peer-Reviewed Original ResearchLow-dose oral minoxidilOral minoxidilExpert consensus statementTopical minoxidilHair lossPediatric patientsConsensus statementModified Delphi processDelphi consensus processEfficacy of topical minoxidilResults of small studiesInternational expert consensus statementsTreating pediatric patientsAdverse effect profileLong-term safetyOff-label useSpecialty consultationOff-label prescribingDelphi processSurvey roundsEvidence-based dataConsensus processExpert panelSublingual minoxidilThird round
2024
Signs of Potential Androgen Excess Across the Lifespan in a US-based Digital Cohort Study
Wolf A, Wang Z, Onnela J, Baird D, Jukic A, Curry C, Fischer-Colbrie T, Williams M, Hauser R, Coull B, Mahalingaiah S. Signs of Potential Androgen Excess Across the Lifespan in a US-based Digital Cohort Study. The Journal Of Clinical Endocrinology & Metabolism 2024, 110: 1667-1679. PMID: 39388314, PMCID: PMC12086404, DOI: 10.1210/clinem/dgae674.Peer-Reviewed Original ResearchPerceptions of Delayed Alopecia Among Breast Cancer Survivors
Premji S, Ruddy K, Vierkant R, Larson N, Loprinzi C, Dulmage B, Lustberg M, Couch F, Olson J, Cathcart-Rake E. Perceptions of Delayed Alopecia Among Breast Cancer Survivors. Clinical Breast Cancer 2024, 25: e170-e177. PMID: 39592290, PMCID: PMC11769767, DOI: 10.1016/j.clbc.2024.09.008.Peer-Reviewed Original ResearchBreast cancer survivorsMayo Clinic Breast Disease RegistryCancer survivorsChemotherapy recipientsStage I-III breast cancerI-III breast cancerBreast cancer diagnosisPersistent bothersome symptomsRespondents' median ageBreast cancer treatmentMental healthDistressing symptomsDisease RegistryCancer diagnosisCohort studyHair lossSurvivorsBreast cancerBothersome symptomsBreastRespondentsSurvey 6 yearsParticipantsBotherCancer treatmentSodium-Dependent Multivitamin Transporter Deficiency
Jiang X, Wang H, Lin Z. Sodium-Dependent Multivitamin Transporter Deficiency. JAMA Dermatology 2024, 160: 993-994. PMID: 39018031, DOI: 10.1001/jamadermatol.2024.1845.Peer-Reviewed Original ResearchEyebrow and Eyelash Loss in Patients With Cancer.
Rose L, Khuhro A, Minta A, Novice M, Novice T, Lustberg M, Ruddy K, Rake E, Loprinzi C, Dulmage B. Eyebrow and Eyelash Loss in Patients With Cancer. Journal Of Drugs In Dermatology 2024, 23: 327-331. PMID: 38709698, DOI: 10.36849/jdd.8003.Peer-Reviewed Original ResearchConceptsPrevention optionsRadiation therapyTopical vasoconstrictorEndocrine therapyEyelash lossTreatment optionsPrescription medicationsCancer treatmentPatientsScalp coolingHair lossRobust researchMadarosisPermanent tattoosTherapyCancerTreatmentEyebrowsEyelash hairScalpOptionsChemotherapyCryotherapyVasoconstrictorDermatologistsThe Alopecia Areata Severity and Morbidity Index (ASAMI) Study
Group A, Moussa A, Bennett M, Wall D, Meah N, York K, Bokhari L, Asfour L, Rees H, Abraham L, Asz-Sigall D, Basmanav F, Bergfeld W, Betz R, Bhoyrul B, Blume-Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Dhurat R, Donovan J, Doroshkevich A, Eisman S, Farrant P, Ferrando J, Gadzhigoroeva A, Green J, Grimalt R, Harries M, Hordinsky M, Irvine A, Jolliffe V, Kaiumov S, King B, Lee J, Lee W, Li J, Lortkipanidze N, McMichael A, Mesinkovska N, Messenger A, Mirmirani P, Olsen E, Orlow S, Ovcharenko Y, Piraccini B, Pirmez R, Rakowska A, Reygagne P, Rudnicka L, Corralo D, Senna M, Shapiro J, Sharma P, Siliuk T, Starace M, Suchonwanit P, Takwale A, Tosti A, Vañó-Galván S, Visser W, Vogt A, Wade M, Yip L, Zhou C, Sinclair R. The Alopecia Areata Severity and Morbidity Index (ASAMI) Study. JAMA Dermatology 2024, 160: 341-350. PMID: 38324292, DOI: 10.1001/jamadermatol.2023.5869.Peer-Reviewed Original ResearchSurvey roundsTool scorePerspectives of patientsDisease impactDelphi study designHistory of anxietyImpaired quality of lifeQuality of lifeScalp hair lossIdentified various determinantsSeverity of Alopecia Tool scoreAssessment ScaleVideo conference meetingsGlobal Assessment ScaleStudy designImpaired qualitySurvey studyVideo conferencing softwareHair lossSuicidal ideationAA severityConference meetingsAlopecia areataSystemic treatmentDisease duration
2023
Hair Transplantation in the United States: A Population-based Survey of Female and Male Pattern Baldness
Knoedler L, Ruppel F, Kauke-Navarro M, Obed D, Wu M, Prantl L, Broer P, Panayi A, Knoedler S. Hair Transplantation in the United States: A Population-based Survey of Female and Male Pattern Baldness. Plastic & Reconstructive Surgery Global Open 2023, 11: e5386. PMID: 37964923, PMCID: PMC10642908, DOI: 10.1097/gox.0000000000005386.Peer-Reviewed Original ResearchHair lossOverall mental healthHair transplantationValuable therapeutic optionExtensive hair lossMale pattern baldnessYears of ageMinimal hair lossSurgical treatmentTherapeutic optionsAndrogenetic alopeciaPattern baldnessStudy participantsMental healthMost participantsCommon typeSurvey of femalesWomenTransplantationFemale participantsUnited StatesSample of individualsMenParticipantsOnline surveyWhen to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
King B, Shapiro J, Ohyama M, Egeberg A, Piraccini B, Craiglow B, Sinclair R, Chen Y, Wu W, Ding Y, Somani N, Dutronc Y. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. British Journal Of Dermatology 2023, 189: 666-673. PMID: 37708254, DOI: 10.1093/bjd/ljad253.Peer-Reviewed Original ResearchSevere alopecia areataBaricitinib-treated patientsPhase III trialsAlopecia areataResponder subgroupBaricitinib 4Hair regrowthIII trialsGrowth mixture modellingTreatment expectationsLate respondersEarly respondersBaseline disease characteristicsTreatment of adultsSALT scoreWeek 52Baseline characteristicsClinical outcomesDisease characteristicsTreatment allocationHair lossPatientsResponse subgroupsRespondersSubgroupsClinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Ko J, Mayo T, Bergfeld W, Dutronc Y, Yu G, Ball S, Somani N, Craiglow B. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata. JAMA Dermatology 2023, 159: 970-976. PMID: 37556146, PMCID: PMC10413213, DOI: 10.1001/jamadermatol.2023.2581.Peer-Reviewed Original ResearchConceptsSevere alopecia areataSALT scoreAlopecia areataWeek 76Response rateWeek 52Week 36Pooled analysisHair lossLong-term extension dataEyebrow hair lossProportion of patientsWeeks of therapyClinician-reported outcomesHigh response rateHair loss scoreSelective JanusAdult patientsClinical outcomesOutcome scoresHair regrowthClinical trialsMAIN OUTCOMETreatment doseBaricitinib41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata
Shapiro J, Ko J, Egeberg A, Somani N, Jedynak J, Torisu-Itakura H, Yu G, Lu N, Craiglow B. 41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata. Journal Of The American Academy Of Dermatology 2023, 89: ab127. DOI: 10.1016/j.jaad.2023.07.511.Peer-Reviewed Original ResearchHair loss during and after breast cancer therapy
Rose L, Lustberg M, Ruddy K, Cathcart-Rake E, Loprinzi C, Dulmage B. Hair loss during and after breast cancer therapy. Supportive Care In Cancer 2023, 31: 186. PMID: 36826602, DOI: 10.1007/s00520-023-07634-5.Peer-Reviewed Original ResearchConceptsTreatment optionsHair lossDistressing side effectsChemotherapy-induced alopeciaCancer therapyBreast cancer therapyEndocrine therapyMajor surgeryPatient counselingTelogen effluviumBreast cancerBreast oncologistsSide effectsPrevention strategiesAlopeciaTherapyChemotherapyPatientsSurgeryOncologistsOptionsEtiologyCancer
2022
Prevalence and gender distribution of trichotillomania: A systematic review and meta-analysis
Thomson HA, Farhat LC, Olfson E, Levine JLS, Bloch MH. Prevalence and gender distribution of trichotillomania: A systematic review and meta-analysis. Journal Of Psychiatric Research 2022, 153: 73-81. PMID: 35802953, DOI: 10.1016/j.jpsychires.2022.06.058.Peer-Reviewed Original ResearchConceptsHair-pulling behaviorMeta-analysesPrevalence estimatesOdds ratioSystematic reviewRandom-effects meta-analysesHair-pullingMeta-analysisSignificant public health impactPublic health impactGender distributionPrevalence dataHair lossEpidemiological studiesHealth impactsIncreased riskEpidemiological samplePrevalenceDatabase searchTrichotillomaniaFemale preponderanceIncidence of Alopecia in Treatment of Women With Uterine Fibroids: Results of Two Phase 3 Trials of Linzagolix [A104]
Al-Hendy A, Taylor H, Catherino W, Stewart E, Bestel E, Garner E. Incidence of Alopecia in Treatment of Women With Uterine Fibroids: Results of Two Phase 3 Trials of Linzagolix [A104]. Obstetrics And Gynecology 2022, 139: 30s-30s. DOI: 10.1097/01.aog.0000826736.08037.1b.Peer-Reviewed Original ResearchPhase 3 trialUterine fibroidsGnRH antagonistHair lossPlacebo-controlled phase 3 trialUterine fibroid-related symptomsFibroid-related symptomsIncidence of alopeciaOral GnRH antagonistPooled safety analysisTreatment of womenConcomitant therapyTreatment discontinuationStudy drugWeek 52Mild alopeciaWeek 24Benign disorderSimilar incidenceLinzagolixSuppression dosesAlopeciaFibroidsTrialsTreatment
2021
Real-world data on usage of scalp cooling for chemotherapy associated alopecia in the United States.
Williams N, Paxman R, Thornhill E, Kassem M, Grimm M, Dulmage B, Cathcart-Rake E, Ruddy K, Pariser A, Gatti-Mays M, Cherian M, VanDeusen J, Stover D, Sardesai S, Wesolowski R, Ramaswamy B, Loprinzi C, Lustberg M. Real-world data on usage of scalp cooling for chemotherapy associated alopecia in the United States. Journal Of Clinical Oncology 2021, 39: e18739-e18739. DOI: 10.1200/jco.2021.39.15_suppl.e18739.Peer-Reviewed Original ResearchScalp coolingNational Comprehensive Cancer NetworkMedical Oncology guidelinesComprehensive Cancer NetworkMajority of patientsOncology guidelinesCategory 2ABreast cancerHair lossCancer NetworkSide effectsChemotherapyLargest reportPatientsReal-world useOlder adultsScalpEuropean SocietyFurther studiesAlopeciaCancerDescriptive statisticsGenitourinaryLungGynecologyAssociation between skin disorders and depression in children and adolescents: A retrospective case-control study
Teichgräber F, Jacob L, Koyanagi A, Shin J, Seiringer P, Kostev K. Association between skin disorders and depression in children and adolescents: A retrospective case-control study. Journal Of Affective Disorders 2021, 282: 939-944. PMID: 33601738, DOI: 10.1016/j.jad.2021.01.002.Peer-Reviewed Original ResearchConceptsRetrospective case-control studyCase-control studyAtopic dermatitis/eczemaSkin disordersAssociated with depressionNail disordersMatched ControlsDisease Analyzer databaseHair lossSex-stratified regression analysesConditional logistic regression modelsChronic skin conditionIndex dateLogistic regression modelsNon-significant associationStudy populationDermatitis/eczemaSkin conditionsAnalyzer databasePediatric practicePigmentation disordersDisordersSkinRegression analysisThree disorders
2020
Geographic disparities in access to scalp cooling for the prevention of chemotherapy-induced alopecia in the United States
Singer S, Tkachenko E, Sharma P, Nelson C, Mostaghimi A, LeBoeuf NR. Geographic disparities in access to scalp cooling for the prevention of chemotherapy-induced alopecia in the United States. Journal Of The American Academy Of Dermatology 2020, 85: 1248-1252. PMID: 32610170, DOI: 10.1016/j.jaad.2020.06.073.Peer-Reviewed Original Research
2018
Methotrexate treatment of generalized granuloma annulare: a retrospective case series
Naka F, Strober B. Methotrexate treatment of generalized granuloma annulare: a retrospective case series. Journal Of Dermatological Treatment 2018, 29: 720-724. PMID: 29488435, DOI: 10.1080/09546634.2018.1447075.Peer-Reviewed Original ResearchConceptsGeneralized granuloma annulareRetrospective case seriesCase seriesMethotrexate treatmentGranuloma annulareAdverse effectsFirst-line therapyEfficacy of methotrexateMajority of patientsAvailable therapeutic modalitiesSmall case seriesIndividual case reportsLow internal validityDisease improvementInitial doseTreatment optionsCase reportComplete clearancePartial clearanceHair lossTherapeutic modalitiesPatientsSkin diseasesControl groupDisease severity
2015
Differential relationships between chronic hormone profiles in pregnancy and maternal investment in rhesus monkey mothers with hair loss in the neonatal period
Dettmer AM, Rosenberg K, Menard MT, El‐Mallah S, Woodward RA, Suomi SJ, Meyer JS. Differential relationships between chronic hormone profiles in pregnancy and maternal investment in rhesus monkey mothers with hair loss in the neonatal period. American Journal Of Primatology 2015, 79: 1-8. PMID: 26496532, PMCID: PMC6528798, DOI: 10.1002/ajp.22489.Peer-Reviewed Original ResearchConceptsHigher hair cortisol concentrationsInfant birth weightHair lossInfant growth rateBirth weightFetal measurementsPregnancy/postpartumSubset of monkeysFemale rhesus monkeysIndicator of wellHair cortisol concentrationsNeonatal periodPregnant monkeysLate pregnancyPerinatal periodPregnancyCortisol concentrationsGreater incidenceRhesus monkeysPostpartum femalesPregnant femalesImportant developmental periodMonkeysMothersPrimate facilities
2014
Cosmetic side effects of antiepileptic drugs in adults with epilepsy
Chen B, Choi H, Hirsch L, Moeller J, Javed A, Kato K, Legge A, Buchsbaum R, Detyniecki K. Cosmetic side effects of antiepileptic drugs in adults with epilepsy. Epilepsy & Behavior 2014, 42: 129-137. PMID: 25513768, DOI: 10.1016/j.yebeh.2014.10.021.Peer-Reviewed Original ResearchConceptsCosmetic side effectsValproic acidSide effectsWeight gainGingival hyperplasiaHair lossPractice-based sampleMedication discontinuationAdult patientsDosage adjustmentFemale patientsNewer AEDsAntiepileptic drugsDifferent AEDsFemale sexMedical historyMedical recordsRisk factorsPhysician reportsAED usePatientsClinical practicePregabalinPatient recordsAEDs
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply